CTRI/2013/09/003956
Recruiting
Phase 3
A Prospective, Comparative, Randomized, Multicenter Study of Peg EPO in the Treatment of Anemia due to Chronic Kidney Disease
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Anemia due to Chronic Kidney Disease
- Sponsor
- Intas Biopharmaceuticals Ltd
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients of either sex with an age \>\= 18 years
- •3\.Have not participated in any other investigational drug trial in the last 3 months
- •4\.Have given informed consent to participate in this study
Exclusion Criteria
- •1\.Patient who have overt gastrointestinal bleeding,or bleeding episode necessitating transfusion within 4 weeks before screening.
- •2\.Patient who have any active malignant disease (except non\-melanoma skin cancer).
- •3\.Patients with known hypersensitivity to mammalian cell\-derived products or Albumin (Human)
- •4\.Patients with uncontrolled hypertension.
- •5\.Patients scheduled for major elective orthopaedic surgery or renal transplant and not participating in an autologous blood predonation
- •programme, patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident or any serious life threatening disease or disorder.
- •6\.Any history or presence of clinically significant disease or any other condition which, in the opinion of the Investigator could jeopardize the safety of the subject or the validity of the study results
- •7\.Patient with any specific disease who are not eligible for the use of erythropoiesis stimulating agent (ESA).
- •8\.Hypersensitivity to the active substance or to any of the excipients
- •9\.Patients who for any reason cannot receive adequate antithrombotic prophylaxis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
A study of Rituximab in patients with Non Hodgkins Lymphoma a type of cancerHealth Condition 1: null- CD20-positive diffuse large B-cell or follicular lymphomaNHL patientsCTRI/2012/03/002502INTAS BIOPHARMACEUTICALS LTD100
Recruiting
Phase 3
A clinical study to determine the efficacy and safety of 101-PGC-005 drug for moderate Corona Virus Disease(Covid-19).Health Condition 1: U071- COVID 19 virus identifiedHealth Condition 2: J988- Other specified respiratory disordersCTRI/2024/01/061531axai Life Sciences Pvt Ltd
Completed
Phase 2
A prospective clinicalstudy to evaluate the efficacy and safety of 101-PGC-005 for moderate COrona VIrus Disease(Covid-19).Health Condition 1: U071- COVID 19 virus identifiedHealth Condition 2: J988- Other specified respiratory disordersCTRI/2022/12/048284AXAI LIFE SCIENCES PVT. LTD.,
Completed
Phase 3
A clinical trial to study the safety and efficacy of test Ranibizumab in patients with visual impairmentHealth Condition 1: H353- Degeneration of macula and posterior poleCTRI/2021/08/035907Enzene Biosciences Limited152
Active, not recruiting
Not Applicable
A Prospective, Randomized, Controlled, Multi-center, (Pilot) Study of Osigraft® in Instrumented Posterolateral FusionsEUCTR2004-000675-34-ESniversity Medical Center Utrecht150